Shockwave Medical, Inc., a medical device company, develops and commercializes intravascular lithotripsy (IVL) technology for the treatment of calcified plaque in patients with peripheral and coronary vascular, and heart valve diseases in the United States and internationally.
The company offers products for the treatment of peripheral artery disease (PAD), including M5 IVL catheter and M5+ IVL catheter, which are five-emitter catheters used in the IVL system in medium-diameter vessels; S4 IVL catheter, a four-emitter catheter for use in the IVL system in small-diameter vessels; and L6 IVL catheter, a six-emitter catheter used for the IVL system in large diameter vessels.
It also provides products for the treatment of coronary artery disease, such as C2 IVL catheter and C2+ IVL catheter that are two-emitter catheters for use in the IVL system; and Reducer, a device to treat refractory angina.
In addition, the company develops the COSIRA-II trial; Shockwave C2 Aero, a coronary IVL catheter; Shockwave Javelin Coronary, a non-balloon-based catheter platform to treat tight, difficult-to-cross coronary lesions; Shockwave L6; Shockwave E8 catheter, to target long peripheral artery lesions; and Shockwave Javelin Peripheral, a non-balloon-based catheter platform to treat tight, difficult-to-cross peripheral lesions.
Further, it offers Shockwave Carotid IVL, a purpose-built IVL system to treat calcified carotid artery lesions; and Shockwave Crescendo, a platform developed to treat calcified, stenotic heart valves.
It serves interventional cardiologists, vascular surgeons, and interventional radiologists through sales representatives and managers, and distributors. The company was incorporated in 2009 and is headquartered in Santa Clara, California. As of May 31, 2024, Shockwave Medical, Inc. operates as a subsidiary of Johnson & Johnson.
